Afatinib (BIBW 2992) development in non-small-cell lung cancer

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib

(2010) Yan Xu et al.   CANCER BIOLOGY & THERAPY

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

(2010) Nobuyuki Yamamoto et al.   Journal of Thoracic Oncology

Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer

(2010) Eckart Laack et al.   LUNG CANCER

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

(2010) Robert C. Doebele et al.   LUNG CANCER

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992

(2010) James F. Spicer et al.   Targeted Oncology

in this issue

(2009)   ANNALS OF ONCOLOGY

Trends in cancer mortality in the elderly in Japan, 1970-2007

(2009) L. Yang et al.   ANNALS OF ONCOLOGY

First- and second-line therapy for advanced nonsmall cell lung cancer

(2009) J-P. Sculier et al.   EUROPEAN RESPIRATORY JOURNAL

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

(2009) Christopher G. Azzoli et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2009) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

(2009) S. A. Perera et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR Mutations in Lung Adenocarcinomas

(2008) Allan R. Li et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE